StockData

Alvotech vs Iovance Biotherapeutics

ALVO and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALVO and IOVA compare

Iovance Biotherapeutics grew revenue faster over the last twelve months (34.5% versus 19.7% for Alvotech).

Iovance Biotherapeutics scores higher on the StockData Score (9 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALVOIOVA
Size and price
Market cap–$3.4B
Share price$4.37$7.53
Change, 1 year−20.4%205%
Change, 5 years−55.8%−59.3%
Beta (5Y)0.371.45
Employees1,000975
StockData Score
Total score39 (better)
Valuation score00
Growth score22
Performance score01 (better)
Health score16 (better)
Dividend score00
Valuation
P/S–10.5×
P/B–4.6×
FCF yield–−8.7%
Fair value–$4.03
Margin of safety–−86.8%
Growth
Revenue growth (TTM)19.7%34.5% (better)
Revenue growth, 5Y average54.5%–
Profitability
Gross margin59.8% (better)48.4%
Operating margin13.3% (better)−92.7%
Net margin–−89.1%
FCF margin−19.6% (better)−91.2%
Return on equity–−40.4%
Return on invested capital–−57.0%
Financial health
Debt / equity–0.00
Net debt / EBITDA10.02–
Interest coverage0.5×–
Current ratio1.654.35 (better)
Altman Z-score–6.70
Piotroski F-score–4
Dividends and buybacks
Buyback yield–−8.6%
Shareholder yield–−8.6%
Ownership
Held by institutions–63.3%
Held by insiders67.7%0.39%
Short interest, % of float–14.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.